Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. (Q38008596)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Incretins as a novel therapeutic strategy in patients with diabetes and heart failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Martin Rutter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Mamas Mamas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

M A Khan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

L Neyses

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

published in

Heart Failure Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

141-148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10741-012-9318-y

31 January 2020

exact match

0 references

cites work

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Diabetes, left ventricular systolic dysfunction, and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Role of diabetes in congestive heart failure: the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Influence of diabetes mellitus on heart failure risk and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Glucose and insulin abnormalities in patients with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Oral antihyperglycemic agents and renal disease: new agents, new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9318-Y

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

21 January 2018

1 reference

12 December 2020

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

12 December 2020

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy

1 reference

12 December 2020

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

1 reference

12 December 2020

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

1 reference

12 December 2020

Establishing pragmatic estimated GFR thresholds to guide metformin prescribing

1 reference

12 December 2020

Incretin-based therapies for type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

1 reference

12 December 2020

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

1 reference

12 December 2020

Emerging role of insulin with incretin therapies for management of type 2 diabetes

1 reference

12 December 2020

Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group.

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

10.1007/S10741-012-9318-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22570104%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference